Tremblay’s Prediction of 80,000% Sales Surge for New Antibiotic to Cure Drug-Resistant PneumoniaAny ideas on what stock is being pitched by Tremblay at Biotech Insider Alert as the ”biggest breakthrough since penicillin?”
Here are some teaser quotes from the ad:
”It happens November 4 at 8:30 a.m. Urgent FDA Meeting Poised to Ignite 80,000% Sales
Surge for Tiny Company!”
”… could displace the entire $45 billion antibiotic sector”
”… the FDA is preparing a rare DOUBLE-SHOT DECISION that could unleash a new ”Star Wars” treatment, worth a projected $45 billion.”
”… the company’s CEO, CFO, and Executive VP – have snapped up nearly 90% of available shares alongside institutions… a legendary billionaire has just INCREASED his position in this tiny company by a staggering 571%.”
”… the FDA has given it a rare ”FAST-TRACK” designation… this special FDA classification gives the company a dominant five-year monopoly!”
This is a discussion topic or guest posting submitted by a Stock Gumshoe reader. The content has not been edited or reviewed by Stock Gumshoe, and any opinions expressed are those of the author alone.
Looking at the clues I think it may be $AKAO.
I actually now think it is $CEMP.
It mentions an FDA decision expected by December 27 .. and CEMP has a PDUFA on that date for Solithera – oral Community-acquired bacterial pneumonia (CABP).
The $27 million is not the market cap, it actually says “this company’s sales are a mere $27 million” … to confuse the readers. No position in CEMP.
So, Cempra Pharmaceutical (CEMP) has a meeting on the 4th. Given the stock action doesn’t look like this huge announcement has been leaked.
http://www.fda.gov/AdvisoryCommittees/Calendar/ucm518797.htm
CEMP : It is eight to 16 times more potent than azithromycin against many bacteria and is active against azithromycin-resistant strains. The activity of solithromycin against resistant strains is driven by its ability to interact with three sites on the bacterial ribosome, compared to the single binding site of first and second generation macrolides. Sound familiar: 3-prong attack and 16x’s more potent